Romiplostim

罗普司亭

Report date: 2026/05/08 20:02:52
First In Class

Base Information

Drug NameRomiplostim
Drug Alias NameRomiplostimum (Amgen/Kyowa Hakko Kirin)洛米洛司亭Romiplostim咯咪珀咯罗米司亭 +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionThrombopoietin receptor agonists
TargetsThrombopoietin receptor
Therapy Area/IndicationsSolid tumoursAcute Radiation SyndromePancytopenia +[19] 
Global Approved IndicationsThrombocytopeniaPurpura, Thrombocytopenic, Idiopathic
Approved Indications in ChinaPurpura, Thrombocytopenic, Idiopathic
Original Approved Country/TerritoryUnited States
Original Approved Date2008/08/22
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesTianjin People'S HospitalCancer Hospital Of Chinese Academy Of Medical SciencesThe Second Affiliated Hospital Of Kunming Medical University +[17] 
Inactive CompaniesKyowa Kirin Co LtdNational Cancer InstituteKyowa Hakko Kirin Co Ltd Takasaki Plant +[8] 
Active IndicationsSolid tumoursAcute Radiation SyndromePancytopenia +[14] 
Inactive IndicationsPurpura, ThrombocytopenicCarcinoma, Non-Small-Cell LungLung Neoplasms +[5] 

Other Information

ATC CodeB02BX04
Related LinksWikipediaDrugBankKEGG